Unicycive Therapeutics, Inc.
NASDAQ:UNCYBiotechnology
-$0.24 today
- Market cap
- $104.19M
- Beta
- 1.73
- P/E (TTM)
- -40.8
- EPS (TTM)
- -$0.17
Volume 1.39M
Average 0.65M
UNCY Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Unicycive Therapeutics, Inc.NASDAQ: UNCY
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q1 FY2026 selling, general & admin of $6.83M rose 17.4% year over year, behind the +37.8% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 37.3% from the prior quarter. Over 3 fiscal years it compounded at +45.9% a year.
Context
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 4 analysts of $5.77M (-71.7%) for the fiscal year ending Dec 2026, a slowdown from the +68.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $6.83M+37.3% QoQ
- Last fiscal yearDec 2025
- $20.4M+68.5% YoY
- LTMMar 2026
- $21.4M+37.8% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 20.4M USD
- Year-over-year change
- +68.5%
- 4-year CAGR
- +62.9%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 20.4M | +68.5% |
| FY2024 | 2024-12-31 | 12.1M | +41.6% |
| FY2023 | 2023-12-31 | 8.55M | +30.2% |
| FY2022 | 2022-12-31 | 6.57M | +126.7% |
| FY2021 | 2021-12-31 | 2.9M | — |
Selling, General & Admin vs competitors
How UNCY compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +37.8% is the highest of 10, against a peer median of -7.7%.
- Over three fiscal years its annual growth of +45.9% compares with a peer median of -0.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $37.33M USD | +8.8% | -81.3% | — | |
| LTM Mar 2026 | $23.53M USD | +30.1% | +11.7% | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $22.61M USD | -10.5% | +40.4% | — |
CBUSCibus, Inc. | LTM Mar 2026 | $22.13M USD | -30.7% | +41.8% | 516.4% |
| LTM Mar 2026 | $21.4M USD | +37.8% | +45.9% | — | |
HYFTMindWalk Holdings Corp. | LTM Jan 2026 | CA$18.43M CAD | +3.9% | +1.8% | 100.4% |
| LTM Mar 2026 | $17.75M USD | +13.9% | — | 451.2% | |
| LTM Mar 2026 | $17.18M USD | -7.7% | -15.7% | 6.7% | |
| LTM Mar 2026 | $16.17M USD | -36.6% | -2.6% | — | |
| LTM Mar 2026 | $15.9M USD | -38.9% | -12.9% | — | |
| Peer median (excluding UNCY) | — | -7.7% | -0.4% | 275.8% | |
Competitors are the stored peer set for UNCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 951K | 675K | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 572K |
| Gross Profit | 0 | 951K | 675K | 0 | (572K) |
| Gross Margin | — | 100.0% | 100.0% | — | — |
| Research & Development | 6.08M | 12.44M | 12.9M | 20.01M | 9.12M |
| Selling, General & Admin | 2.9M | 6.57M | 8.55M | 12.1M | 20.4M |
| Operating Expenses | 8.98M | 19M | 21.45M | 32.12M | 28.95M |
| Depreciation & Amortization | 13K | 161K | 284K | 428K | 572K |
| EBITDA | (9.38M) | (17.89M) | (30.18M) | (36.23M) | (25.91M) |
| EBITDA Margin | — | -1881.3% | -4470.8% | — | — |
| Operating Income | (8.98M) | (18.05M) | (20.77M) | (32.12M) | (29.52M) |
| Operating Margin | — | -1898.2% | -3077.6% | — | — |
| Interest Income | 0 | 0 | 615K | 1.26M | 1.01M |
| Interest Expense | 628K | 6K | 82K | 71K | 71K |
| Other Income / Expenses | (1.04M) | (6K) | (9.77M) | (4.61M) | 2.96M |
| Income Before Tax | (10.02M) | (18.06M) | (30.54M) | (36.73M) | (26.56M) |
| Pre-Tax Margin | — | -1898.8% | -4525.0% | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (10.02M) | (18.06M) | (30.54M) | (36.73M) | (26.56M) |
| Net Margin | — | -1898.8% | -4525.0% | — | — |
| EPS (Basic) | (8.60) | (1.20) | (1.28) | (5.60) | (1.67) |
| EPS (Diluted) | (8.60) | (1.20) | (1.28) | (5.60) | (1.67) |
| Weighted Avg Shares | 1.17M | 1.51M | 2.45M | 6.7M | 158.87M |
| Weighted Avg Shares (Diluted) | 1.17M | 1.51M | 2.45M | 6.7M | 158.87M |
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
Intrinsic Alpha fair value
Locked
Current Price
$3.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.